Drug intelligence / Profile preview

Factor VIIa (recombinant)

Development stage: Preclinical
Lead developer: Savara
Modality: Recombinant Proteins and Enzymes
Administration: Inhalation

Overview

Factor VIIa (recombinant) is a protein involved in the coagulation cascade. When administered, it binds to tissue factor at the site of injury, activating Factor X and leading to thrombin generation and fibrin clot formation. The inhaled formulation, known by the development name Alveodex, is being developed to locally promote hemostasis in the lungs for the treatment of diffuse alveolar hemorrhage (DAH), a life-threatening condition characterized by bleeding into the lung alveoli.

Other names: inhaled Factor VIIa

Targets

F9 (Coagulation Factor IX)F3 (Tissue factor)F10 (Factor Xa)

Beyond the preview

Go deeper on Factor VIIa (recombinant).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Factor VIIa (recombinant).

Explore the full profile